PubMed HealthSearch

Biomedical subjects

N Dorny

Publications and source records attributed to N Dorny.

2 recordsLinked to original sources

Left ventricular function changes during pharmacological and physiological interventions and routine activities monitored in healthy volunteers by a portable radionuclide probe (VEST).

A miniaturized radionuclide cardiac probe incorporated in a semi-rigid plastic chest garment has made ambulatory left ventricular (LV) function evaluation possible, with gated nuclear data being stored on tape together with electrocardiographic data, for subsequent off-line processing. After red blood cell labelling with 555 MBq (15 mCi) 99mTc and standard gated blood pool imaging in 45 degrees LAO, we performed a continuous monitoring of LV function in 20 healthy male volunteers (age range: 22-25 years), in resting control conditions as well as during activities (standing, walking, climbing stairs) and after interventions (isosorbide dinitrate intake, Trendelenburg position, inflation of cuffs around the thighs). VEST-monitoring proved to be a reliable method that gave reproducible results: changes of ejection (EF) in basal conditions were lower than 5% in 95% of the patients. Changes in LV function caused by daily activities were easily demonstrated. While standing effected no significant EF changes, walking and climbing increased EF by 6.9% (p less than 0.05) and 21.2% (p less than 0.05) respectively. Changes in LV volumes caused by alterations in venous return were also demonstrated. Compared with baseline, Trendelenburg increased end-diastolic volume (EDV) by 2.9% while isosorbide dinitrate and inflation of cuffs decreased it by 5.7% and 2.2% respectively.

Adult

Facts about combination therapy in NIDDM: insulin + oral antidiabetic agents.

Recent recommendations in textbooks suggest the use of the combination of insulin treatment with oral antidiabetic agents in NIDDM, especially in secondary failures and insulin resistance with exogenous insulin. This new view in treatment policy is based on literature data in C-peptide positive IDDM patients. Better metabolic control with lower exogenous insulin dosages could also be obtained in NIDDM. If no medical contraindication for drug treatment exists (liver or renal insufficiency, drug interactions, etc.), a combination therapy trial can be considered as an intermediate step between oral antidiabetic agents alone and insulin as monotherapy. Long-term maintenance of endogenous secretion and limited peripheral hyperinsulinism can be considered as potential benefits of this combination therapy.

Blood Glucose